Equities analysts expect that Tabula Rasa HealthCare Inc (NASDAQ:TRHC) will post earnings of $0.26 per share for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Tabula Rasa HealthCare’s earnings, with the highest EPS estimate coming in at $0.30 and the lowest estimate coming in at $0.21. Tabula Rasa HealthCare reported earnings per share of $0.08 in the same quarter last year, which would suggest a positive year over year growth rate of 225%. The firm is scheduled to issue its next earnings report on Monday, November 5th.
According to Zacks, analysts expect that Tabula Rasa HealthCare will report full-year earnings of $0.82 per share for the current fiscal year, with EPS estimates ranging from $0.65 to $1.04. For the next year, analysts anticipate that the company will report earnings of $1.08 per share, with EPS estimates ranging from $0.88 to $1.22. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Tabula Rasa HealthCare.
Tabula Rasa HealthCare (NASDAQ:TRHC) last posted its earnings results on Tuesday, August 7th. The company reported $0.20 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.08 by $0.12. Tabula Rasa HealthCare had a negative net margin of 16.78% and a positive return on equity of 4.55%. The firm had revenue of $48.60 million for the quarter, compared to analysts’ expectations of $46.73 million.
A number of equities research analysts recently commented on the stock. MED lifted their price target on shares of Tabula Rasa HealthCare from $47.00 to $63.00 and gave the stock an “outperform” rating in a report on Monday, May 21st. Piper Jaffray Companies reiterated an “overweight” rating and issued a $46.00 price objective on shares of Tabula Rasa HealthCare in a research note on Wednesday, May 9th. Zacks Investment Research upgraded shares of Tabula Rasa HealthCare from a “hold” rating to a “buy” rating and set a $74.00 price objective for the company in a research note on Saturday. Citigroup lifted their price objective on shares of Tabula Rasa HealthCare from $57.00 to $76.00 and gave the company a “buy” rating in a research note on Thursday. Finally, BidaskClub upgraded shares of Tabula Rasa HealthCare from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, April 24th. One analyst has rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $55.36.
Shares of Tabula Rasa HealthCare stock traded up $0.46 during mid-day trading on Tuesday, hitting $66.25. 371,883 shares of the stock were exchanged, compared to its average volume of 314,938. Tabula Rasa HealthCare has a 12 month low of $16.72 and a 12 month high of $70.15. The company has a quick ratio of 0.41, a current ratio of 0.36 and a debt-to-equity ratio of 0.11. The stock has a market cap of $1.33 billion, a P/E ratio of 346.26, a P/E/G ratio of 5.85 and a beta of 2.03.
In other Tabula Rasa HealthCare news, CEO Calvin H. Knowlton sold 8,000 shares of the business’s stock in a transaction on Tuesday, August 7th. The shares were sold at an average price of $60.54, for a total value of $484,320.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Bruce Luehrs sold 85,842 shares of the business’s stock in a transaction on Tuesday, May 22nd. The stock was sold at an average price of $50.66, for a total transaction of $4,348,755.72. The disclosure for this sale can be found here. Insiders have sold a total of 233,842 shares of company stock valued at $12,070,820 over the last 90 days. Company insiders own 14.00% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the business. Koch Industries Inc. bought a new position in Tabula Rasa HealthCare in the first quarter worth about $244,000. Principal Financial Group Inc. bought a new position in Tabula Rasa HealthCare during the first quarter valued at approximately $3,870,000. The Manufacturers Life Insurance Company lifted its position in Tabula Rasa HealthCare by 18.5% during the first quarter. The Manufacturers Life Insurance Company now owns 9,297 shares of the company’s stock valued at $360,000 after purchasing an additional 1,453 shares during the period. Westwood Management Corp IL bought a new position in Tabula Rasa HealthCare during the second quarter valued at approximately $849,000. Finally, Dana Investment Advisors Inc. bought a new position in Tabula Rasa HealthCare during the second quarter valued at approximately $2,557,000. 65.07% of the stock is owned by institutional investors and hedge funds.
Tabula Rasa HealthCare Company Profile
Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. It offers medication risk management, pharmacy cost management, and medicare risk adjustment services. The company offers its technology-enabled products and services to prescribers, pharmacists, and healthcare organizations for medication risk management and risk adjustment.
Recommended Story: Why Dividend Stocks May Be Right for You
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.